By using this website you allow us to place cookies on your computer. Please read our Privacy Policy for more details.
Publication Date: May 2001
Publisher: Henry J. Kaiser Family Foundation
Author(s):
Research Area: Health
Type: Report
Coverage: United States
Abstract:
This report, written by Marilyn Moon and Matthew Storeygard of the Urban Institute, estimates the potential cost of targeting drug benefits to low-income Medicare beneficiaries and those with catastrophic drug expenses and discusses some of the key programmatic issues that could arise under this approach.
The authors predict that a targeted and comprehensive drug benefit would likely help more than half of the 11.3 million low-income beneficiaries who lack drug coverage through Medicaid or an employer-sponsored plan. Covering this population and offering catastrophic protection to beneficiaries with extremely high out-of-pocket drug expenses would require an estimated $345 billion over ten years.